Evidence map›Paper›PMID 42654045›Full record

ReviewPharmaceutics2026

Clinical Implications of

Silvia R Vitale, Melissa Drago, Federica Martorana, Chiara Conti, Michele Massimino, Stefania Stella, Cristina Tomarchio, Paolo Vigneri, Livia Manzella

Abstract readReview
In one paragraph

Review in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Silvia R VitaleCenter of Experimental Oncology and Hematology, A.O.U. Policlinico "G. Rodolico-S. Marco", 95123 Catania, Italy.ORCID 0000-0002-7948-3580
Melissa DragoDepartment of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
Federica MartoranaDepartment of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.ORCID 0000-0001-5062-2914
Chiara ContiDepartment of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.ORCID 0009-0007-7219-2477
Michele MassiminoCenter of Experimental Oncology and Hematology, A.O.U. Policlinico "G. Rodolico-S. Marco", 95123 Catania, Italy.ORCID 0000-0001-5896-8573
Stefania StellaCenter of Experimental Oncology and Hematology, A.O.U. Policlinico "G. Rodolico-S. Marco", 95123 Catania, Italy.
Cristina TomarchioCenter of Experimental Oncology and Hematology, A.O.U. Policlinico "G. Rodolico-S. Marco", 95123 Catania, Italy.ORCID 0000-0002-1044-1008
Paolo VigneriDepartment of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
Livia ManzellaCenter of Experimental Oncology and Hematology, A.O.U. Policlinico "G. Rodolico-S. Marco", 95123 Catania, Italy.

Funding

Gilead Sciences (United States) project n° 0389767, Dec 16, 2024
6 · The paper itself

Abstract

Pharmacogenetics has transformed oncology by enabling personalized, effective and safer use of anticancer therapies. Among clinically relevant pharmacogenetic biomarkers, polymorphisms in the

Indexed as

adverse eventsanticancer therapydrug–drug interactionspharmacogeneticsUGT1A1 polymorphisms

Identifiers

PMID42654045
PMCPMC13516210

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.